The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma.
Marina Tschaika
Employment or Leadership Position - MOLOGEN
Hans-Joachim Schmoll
No relevant relationships to disclose
Jorge Riera-Knorrenschild
No relevant relationships to disclose
Dieter Nitsche
No relevant relationships to disclose
Jorg Trojan
No relevant relationships to disclose
H. Kröning
No relevant relationships to disclose
Fritz Albert Maiwirth
No relevant relationships to disclose
Marcel Reiser
No relevant relationships to disclose
Matthias Schroff
Employment or Leadership Position - MOLOGEN
Ekaterina Weith
Employment or Leadership Position - MOLOGEN
Manuel Schmidt
Employment or Leadership Position - MOLOGEN
Burghardt Wittig
Consultant or Advisory Role - MOLOGEN